Psoriatic arthritis, axial spondyloarthritis and rheumatoid arthritis in Norway: nationwide prevalence and use of biologic agents
Authors' conclusion
In Norway, the combined prevalence of PsA, axSpA, and RA was over 1.5%.
Study context
- Population
- Norwegian adult population (age ≥18), Norwegian Patient Registry
- Exposure
- PsA vs axial spondyloarthritis (axSpA) vs rheumatoid arthritis (RA)
- Outcome
- Point prevalence of PsA, axSpA and RA
- Follow-up
- 1st of January 2017
Methodological detailsnationwide, registry-based
- Nationwide
- Registry-based
Main finding
As reported in the abstract
Point prevalence
- Any of these diseases in total
- 1.56%
Observational data: associations, not effects.
Further findings
Point prevalence among women
Point prevalence among men
Use of bDMARDs · 2017
Use of bDMARDs · 2017
- Biologics more frequent in younger age groups in all three diseases, more infrequent especially after age ≥55 years
Original publication
Psoriatic arthritis, axial spondyloarthritis and rheumatoid arthritis in Norway: nationwide prevalence and use of biologic agents. Scand J Rheumatol. Published 11 January 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →